{"id":"W4411286445","doi":"10.1158/1557-3265.sabcs24-p5-03-01","title":"Abstract P5-03-01: Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Breast cancer; Phases of clinical research; Cancer; Internal medicine; Open label; Randomized controlled trial; Clinical trial","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002772357,0.002133393,0.002354941,0.0004723704,0.0005989687,0.001611257,0.001191373,0.001908498,0.005812697],"category_scores_gemma":[0.001624132,0.0008218466,0.001855131,0.0004438414,0.001552466,0.001327458,0.0004145899,0.005191013,0.001495349],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009734808,"about_ca_system_score_gemma":0.001798732,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001662633,"about_ca_topic_score_gemma":0.003736169,"domain_scores_codex":[0.9992686,0.0003976789,0.00002988856,0.0001220554,0.00006711868,0.0001146631],"domain_scores_gemma":[0.9988318,0.000254586,0.0002653617,0.00009455891,0.00008729013,0.0004663439],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9476977,0.0246211,0.00094593,0.0003544273,0.0008638183,0.00008229216,0.0001132946,0.0005056026,0.008603597,0.000169347,0.001909211,0.01413375],"study_design_scores_gemma":[0.9060805,0.0901171,0.001803519,0.00001327485,0.000217746,0.00004599935,0.00002686426,0.0004298837,0.000570901,0.000115338,0.0005658279,0.00001313186],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850033,0.001781122,0.00111112,0.0008871905,0.0003060848,0.005445777,0.002693815,0.0002307674,0.002540727],"genre_scores_gemma":[0.9772134,0.00169455,0.003097938,0.002409928,0.0005320612,0.006179916,0.00358511,0.00008384686,0.005203227],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005812697,"threshold_uncertainty_score":0.01944542,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1548699941123187,"score_gpt":0.5548477553664776,"score_spread":0.3999777612541588,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}